Teva Pharmaceutical Industries Ltd. (TEVA)

12.25
0.06 0.49
NYSE : Health Technology
Prev Close 12.19
Open 12.10
Day Low/High 11.68 / 12.31
52 Wk Low/High 6.07 / 13.76
Volume 14.34M
Avg Volume 10.87M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 12.57B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Amarin's Huge Rally: Here's Why the Stock Is Soaring and How to Trade It

Amarin's Huge Rally: Here's Why the Stock Is Soaring and How to Trade It

For equity holders in Amarin, now's the time to be implementing my 'Jensen Rules.'

How I See Biotechs Now

How I See Biotechs Now

I expect deal volume to have a substantial uptick before the end of 2018 rolls around.

Retailers Offering Safe Havens

"Despite a voluminous and often fervent literature on "income distribution," the cold fact is that most income is not distributed: It is earned."  -- Thomas Sowell Markets are pretty much trading at the same levels as our last update as it looks lik...

Five-Day Winning Streak in Stocks Expected to Continue

Five-Day Winning Streak in Stocks Expected to Continue

On Thursday alone, we experience both free-fall, as well as a raucous rally.

Jim Cramer: The SEC Should Admit It Goofed With These Crazy Instruments

Jim Cramer: The SEC Should Admit It Goofed With These Crazy Instruments

We used to think of what's in the public's interest when it comes to securities.

Clearly, Warren Buffett Loves Apple's Stock

Clearly, Warren Buffett Loves Apple's Stock

Warren Buffett continues to eat up Apple's stock. He also has bought a stake in struggling generics drug maker Teva.

What's Behind the Hound of Hades' Stock Market Rampage

What's Behind the Hound of Hades' Stock Market Rampage

The free market is going to take back control of interest rates.

This Is the Best Advice We Can Give After the Dow Jones Industrial Average Crash

This Is the Best Advice We Can Give After the Dow Jones Industrial Average Crash

The stock market continues to be under considerable pressure. Here is one thing not to do right now amidst the carnage.

Are Politics and Proxy Firms Killing Your Investment Returns?

Are Politics and Proxy Firms Killing Your Investment Returns?

Gains are being left on the table as firms and investors let their politics or social concerns get the better of them.

Generic-Drug Stocks Are Looking Sickly

I'm seeing some weakness in generic-drug stocks -- i.e., Teva Pharmaceuticals , Mylan and Mallinckrodt -- based on a New York Times article that hospitals might move into the generic-drug business.

Try This Pair of Biotech Trades

Try This Pair of Biotech Trades

Teva and Mallinckrodt both lost over 50% of their value in 2017 and might catch some momentum here.

Dow Jumps to New Intraday High as Deal News Boosts Wall Street

Dow Jumps to New Intraday High as Deal News Boosts Wall Street

Stocks were slightly higher.

Wrap Up

I was out of the office most of the day. To me the most interesting asset class move was in bonds -- with yields down by over five basis points. The 10-year yield fell to under 2.35% though the 2s/10s curve was flat. While municipals rallied in pric...

SNF Wins The Night But Loses Viewers: LIVE MARKETS BLOG

SNF Wins The Night But Loses Viewers: LIVE MARKETS BLOG

The broadcast scored an 11.6 metered rating, tops on the night, but short of last week's total.

Staying Liquid

I missed very little and was better served at my "liquid" lunch meeting. Bitcoin was being bitcoin (+17%) with prices contrasting wildly by Exchanges -- a signpost that volatility will be with this commodity for some time. I have a double dose of Bo...

Mid-Afternoon Observations

Some mid afternoon observations:   * Small yield flattening in today's session and little change in bond yields. * High yield is slipping a bit. * The U.S. Dollar is strengthening after morning weakness. * Oil down after weeks of strength (-$0.76/ba...

Markets Close 'Green' on Black Friday

Markets Close 'Green' on Black Friday

While shoppers were busy looking for bargains at the mall, traders were busy doing the same on Wall Street.

Wells Fargo Labels Teva in 'Survival Mode'

This morning Wells Fargo research describes Teva Pharmaceutical Industries as being "in survival mode."   The brokerage expects a 20% reduction in employment (this is broadly anticipated).    The company reported in Israel that Teva currently doesn'...

Why Teva Will Be Hard Pressed to Maintain Its Dividend in the Long Term

Why Teva Will Be Hard Pressed to Maintain Its Dividend in the Long Term

The troubled drug firm slashed its dividend by 75% in August, but its current dividend payout ratio and yield can tell us a lot about the future.

Biotech Stocks to Watch: Part 1

Biotech Stocks to Watch: Part 1

Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.

Here's What's Up This A.M.

The Nasdaq (QQQs) turn slightly negative as most of the FANGs reverse lower.   Retail, generics (Teva and Mylan ), big pharma (Merck and Bristol-Myers Squibb ) and biotech (Allergan , Gilead Sciences , Celgene ) are conspicuous to the downside.   Co...

Recommended Reading: Teva

Barron's Online: Teva - It's Never Too Late to Sell 

Teva Takes Another Analyst Hit

HSBC has downgraded Teva Pharmaceutical Industries to reduce, lowering its price target from $26 to $6, which automatically disqualifies me from paying attention to the analyst!   Seriously, though, the brokerage reduces estimates to reflect likely ...

From The Street of Dreams

Wells Fargo has lowered their price target for Teva Pharmaceutical   to $12/share after the disappointing third-quarter results and fourth-quarter guidance.  

Potholes in the Market

Despite stocks near their all-time records, there are more potholes (this week) than observed on Second Avenue in the Upper East Side in New York City.  Today's potholes:  * Optical (Oclaro guidedown) * FANG (reaction to earnings) * Retail (again) *...

This Allergan Bull Reluctantly Waves the White Flag and Exits the Stock

This Allergan Bull Reluctantly Waves the White Flag and Exits the Stock

Looking ahead, Allergan may be more vulnerable than suggested by management or believed by analysts.

My Trader Side Prefers Jay Powell; My Economist Side Likes Rules: Market Recon

My Trader Side Prefers Jay Powell; My Economist Side Likes Rules: Market Recon

My economist side would clearly prefer a rules-based approach toward monetary policy.

Say No to Teva

There continues to be a lot of interest in Teva Pharmaceutical Industries . I have received a number of additional inquiries via email again over the weekend.  Here was my most recent analysis from early October.  At the core of my concern is that c...

5 Amazing Dividend Stocks in This Uncertain Market

5 Amazing Dividend Stocks in This Uncertain Market

And a review of the previous five I recommended.